Drug Development / Biotech
AccelDx is a medical device company developing pScreen™, a disruptive blood testing platform for the diagnosis and management of medical conditions in the Home/Point-of-Care setting. AccelDx’s solution enables physicians/patients to manage diseases in a timely and effective manner, thereby reducing cost and hospitalizations. AccelDx is currently focusing on pScreen-BNP™ for the in home daily monitoring of heart condition to prevent heart failure (HF) related re-hospitalizations: an untapped market opportunity of $1.9B.
BIOSAFE, Inc. (acquired by Gelest)
BIOSAFE’s technology provides products with microbiological protection. Through a patented and EPA registered antimicrobial technology, products that include BIOSAFE are permanently protected bacteria, mold and mildew, algae, and even certain viruses. BIOSAFE works in close partnership with personnel from design and development and end-user marketing to insure simple integration and communication of strong product advantage.
Carmell Therapeutics Corporation
Carmell has developed a method of manufacturing biologically-active plastic materials from blood plasma. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell is focused on products for the sports medicine market with devices for the repair of tendon and cartilage injuries.
Cellumen, Inc. (Acquired by Apredica/Cyprotex)
Cellumen is the Systems Cell Biology company that is focused on delivering cellular models of disease and cytotoxicity that will revolutionize the drug discovery process and improve the quality of compounds entering clinical trials. The same systems cell biology approach is also being developed to optimize personalized medicine for clinical trials. Cellumen was acquired by Apredica/Cyprotex 8/4/10.
Cognition Therapeutics, Inc.
Cognition Therapuetics Inc. (CogRx) is a discovery and development pharmaceutical company focused on novel small molecule disease-modifying and symptomatic treatments for neurodegenerative disorders. Cognition Therapeutics has pioneered the discovery and development of new drugs acting at new targets to halt disease progression and improve symptoms in neurodegenerative disorders.
Immunetrics is a bio-simulation company, founded in 2001, that specializes in in silico disease modeling. Immunetrics modeling technology provides critical information to drug developers to accelerate and improve the drug discovery and development process, particularly in the identification of clinically relevant biomarkers. Immunetrics has developed a predictive software model of the human response to inflammation and coagulation, which enables drug discovery and development firms to gain comprehensive insights into a compound before investing significant resources into time-intensive and costly animal testing and human clinical trials.
Knopp Biosciences LLC
KNOPP BIOSCIENCES is a drug discovery and development company focused on delivering breakthrough treatments in neurological disorders through innovation, experience and partnership. Knopp’s lead compound, KNS-760704 (dexpramipexole), is currently in late-stage clinical development for amyotrophic lateral sclerosis, with additional indications under investigation.
RedPath Integrated Pathology, Inc. (Acquired by PDI Inc.)
RedPath is a genomics-based cancer diagnostic company that provides comprehensive molecular analysis to resolve challenging diagnostic dilemmas. The company’s CLIA licensed, CAP certified laboratory delivers actionable diagnostic information that enables physicians to make personalized, effective treatment decisions for their patients.
Sharp Edge Labs, Inc.
Sharp Edge Labs is an assay development company delivering better assays for studying cell-surface proteins. The company’s patenteTargeted Sensor technology provides a more accurate and detailed picture of protein trafficking, a process that is critical to the biology of the largest class of pharmaceutical drug targets (GPCRs, Ion Channels and Transporters). The company offers reagents and kits, assays and cell-lines, and assay services including development of new assays for proprietary targets.
Thar Pharmaceuticals, Inc. (acquired by Grünenthal)
Thar Pharmaceuticals reinvents known, safe, on-the-market drugs by improving their clinical performance and economic benefits. We focus on transforming intravenous (IV) drugs into orally administered drugs, thus eliminating the cost of IV drug administration, a $34 billion annual worldwide healthcare cost paid by health systems, patients and insurers.